Usana Health Sciences
USNA
Usana Health Sciences (USNA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jul 4, 2026
- EPS actual
- −$0.07
- EPS estimate
- $0.43
- EPS surprise
- −116.28%
- Revenue surprise
- −4.99%
- Revenue
- $223.3M
- Revenue estimate
- $235.0M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.43 | −$0.07 | −116.28% | $223.3M | SEC |
| Q1 2026 | May 5, 2026 | $0.44 | $0.61 | +38.64% | $250.0M | SEC |
| Q4 2025 | Feb 18, 2026 | $0.41 | $0.60 | +46.34% | $226.2M | SEC |
| Q3 2025 | Oct 22, 2025 | −$0.15 | −$0.15 | +0.00% | $214.0M | SEC |
| Q2 2025 | Jul 22, 2025 | $0.54 | $0.74 | +37.04% | $235.8M | SEC |
| Q1 2025 | Apr 22, 2025 | $0.70 | $0.73 | +4.29% | $249.5M | SEC |
| Q4 2024 | Feb 25, 2025 | $0.49 | $0.64 | +30.61% | $213.6M | SEC |
| Q3 2024 | Oct 22, 2024 | $0.49 | $0.56 | +15.46% | $200.0M | SEC |
| Q2 2024 | Jul 23, 2024 | $0.58 | $0.54 | −7.26% | $212.9M | SEC |
| Q1 2024 | Apr 30, 2024 | $0.69 | $0.86 | +24.64% | $227.8M | SEC |
| Q4 2023 | Feb 6, 2024 | $0.52 | $0.87 | +68.93% | $221.1M | SEC |
| Q3 2023 | Oct 24, 2023 | $0.59 | $0.59 | −0.49% | $213.4M | SEC |
| Q2 2023 | Jul 25, 2023 | $0.70 | $0.89 | +27.97% | $238.2M | SEC |
| Q1 2023 | Apr 25, 2023 | $0.77 | $0.95 | +24.04% | $248.4M | SEC |
| Q4 2022 | Feb 7, 2023 | $0.35 | $0.66 | +88.57% | $228.0M | SEC |
| Q3 2022 | Oct 25, 2022 | $0.89 | $0.78 | −12.36% | $233.3M | — |
| Q2 2022 | Jul 26, 2022 | $1.05 | $1.00 | −4.76% | $264.5M | — |
| Q1 2022 | Apr 26, 2022 | $1.14 | $1.15 | +0.88% | $272.9M | — |
| Q4 2021 | Feb 8, 2022 | $1.28 | $1.03 | −19.53% | $267.3M | — |
| Q3 2021 | Oct 26, 2021 | $1.30 | $1.36 | +4.62% | $274.4M | — |
Quarterly revenue
Frequently asked questions
When did Usana Health Sciences (USNA) last report earnings?
Usana Health Sciences last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did USNA beat earnings estimates?
No. Usana Health Sciences reported EPS of −$0.07 for Q2 2026 against a $0.43 estimate — a 116.28% miss.
How much revenue did USNA report last quarter?
Usana Health Sciences reported $223.3M in revenue for Q2 2026, against a consensus estimate of $235.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.